目的 观察喜炎平注射液联合阿奇霉素对小儿支原体肺炎的抗炎、抗支原体作用及安全性，探讨治疗支原体肺炎的作用机制，为临床医治提供新的依据。方法 将72例支原体肺炎患儿随机分成治疗组和对照组，治疗组36例，对照组36例，对照组使用阿奇霉素治疗，治疗组在对照组的基础上予喜炎平注射液静脉滴注，疗程为7~11 d；比较两组患者治疗后的中医证候疗效评价、发热消失时间、咳嗽消失时间等指标，检测患者血清中炎症因子水平。结果 经过7~11 d治疗，两组患者症状均有所改善，治疗组显效率明显优于对照组（P<0.05），治疗组治疗后中医证候疗效评价、发热消失时间、咳嗽消失时间与对照组比较均有统计学差异（P<0.05）；治疗后，两组的白细胞介素-10（IL-10）、IL-4均明显降低，IL-2、γ干扰素（IFN-γ）均明显升高；患者治疗后血清IL-10、IL-2、IL-4、IFN-γ指标两组间比较差异无统计学意义（P>0.05）。结论 喜炎平注射液联合阿奇霉素能够显著改善风热郁肺证和痰热闭肺证的支原体肺炎患儿中医临床症状，提高中医证候疗效，且安全性较好，无明显不良反应。

Objective To observe the anti-inflammatory and anti-mycoplasma effects and safety of Xiyanping Injection on mycoplasma pneumonia in children, and to explore the mechanism of treatment of mycoplasma pneumonia, so as to provide a new basis for clinical treatment. Methods A total of 72 children with mycoplasma pneumonia were randomly divided into treatment group and control group, 36 cases in treatment group and 36 cases in control group. The control group was treated with Azithromycin. The treatment group was treated with Xiyanping intravenous drip on the basis of the control group and observed for 7 to 11 d. The therapeutic effects of TCM syndromes, the disappearance time of fever and cough were compared between the two groups to detect serum levels of inflammatory factors. Results After 7 to 11 d of treatment, the symptoms of the two groups were improved, and the marked efficiency of the treatment group was significantly better than that of the control group (P < 0.05). There were significant differences in the evaluation of TCM syndromes, the disappearance time of fever and cough between the treatment group and the control group (P < 0.05). After treatment, interleukin-10 (IL-10) and interleukin-4 (IL-4) were significantly decreased in both groups, while IL-2 and interferon-gamma (IFN-γ) were significantly increased in both groups (P > 0.05). There was no significant difference in serum IL-10, IL-2, IL-4, and IFN-γ between the two groups after treatment (P > 0.05). Conclusion Xiyanping Injection combined with Azithromycin can significantly improve the clinical symptoms of mycoplasma pneumonia in children with wind-heat stagnation of lung syndrome and phlegm-heat obstruction of lung syndrome, and improve the curative effect of traditional Chinese medicine syndromes,with better safety and no obvious adverse reactions.

R287.5

河南省高等学校重点科研项目（10104435）